ArticleCancer research2017
SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer.
Abstract read
In one paragraph
Article in Cancer research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers.
0numbers the graph read from it
0cells of the map it votes in
92citing papers in PubMed
12.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
92 citing papers in PubMed, 141 citations in OpenAlex.
- Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance.British journal of cancer · 2019Trial
- Aptamer-Based Heterobifunctional Targeted Degraders in Disease Treatment.Molecules (Basel, Switzerland) · 2026Review
- Synergistic Regulation of Tumor Immunity by Integrins and Lectins: From Molecular Mechanisms to Dual-Targeted Therapy.International journal of molecular sciences · 2026Review
- A three-gene signature correlated with MAPK/ERK activation characterizes acquired resistance to EGFR-tyrosine kinase inhibitors in non-small cell lung cancer.Oncology letters · 2026Article
- Inhibition of PGC1β-dependent mitochondrial biogenesis enhances EGFR-targeted therapy in lung cancer.EMBO molecular medicine · 2026Article
- Hypoxia-activated PROTAC for dual inhibition of FAK and EGFR enables synergistic mechano-chemical cancer therapy.Neoplasia (New York, N.Y.) · 2026Article
- Salvianolic Acid A Induces Ferroptosis in Non-Small Cell Lung Cancer via the SRC/YAP/GPX4 Axis.International journal of molecular sciences · 2026Article
- TLE1 as a key regulator of osimertinib resistance and EMT in lung adenocarcinoma: implications for prognosis and immunotherapy response.Hereditas · 2026Article
- The resistance landscape of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer: molecular mechanisms and novel therapeutic strategies.Translational lung cancer research · 2026Review
- Traditional Chinese medicine reprograms the tumor microenvironment to overcome EGFR-TKI resistance: mechanisms and therapeutic perspectives.Frontiers in pharmacology · 2026Review
- Profiling of Extracellular Vesicles of Non-Small Cell Lung Cancer Reveals Proteins Associated With Osimertinib Resistance.Journal of extracellular vesicles · 2026Article
- SOS1 inhibition suppresses the emergence of osimertinib resistance to generate a durable response inScience signaling · 2025Article
- Drug tolerance and persistence to EGFR inhibitor treatment are mediated by an ILK-SFK-YAP signaling axis in lung adenocarcinoma.Oncogene · 2025Article
- A CMTM6 Nanobody Overcomes EGFR-TKI Resistance in Non-Small Cell Lung Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Exploiting YES1-Driven EGFR Expression Improves the Efficacy of EGFR Inhibitors.Molecular cancer research : MCR · 2025Article
- Exploring the role of YES1 kinase in regulating cisplatin resistance through iTRAQ-based quantitative proteomic analysis in urothelial carcinoma.American journal of cancer research · 2025Article
- Novel FAK inhibitors suppress tumor growth and reverse EGFR-TKI resistance in non-small cell lung cancer.Cancer drug resistance (Alhambra, Calif.) · 2025Article
- Article
- Recycling machinery of integrin coupled with focal adhesion turnover via RAB11-UNC13D-FAK axis for migration of pancreatic cancer cells.Journal of translational medicine · 2024Article
- Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer.British journal of cancer · 2024Article
32 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Eiki IchiharaDepartment of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee.
David WestoverDepartment of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee.
Catherine B MeadorDepartment of Cancer Biology, Vanderbilt University School of Medicine, Nashville, Tennessee.
Yingjun YanDepartment of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee.
Joshua A BauerDepartment of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee.
Pengcheng LuDepartment of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee.
Fei YeDepartment of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee.
Amanda KulickAnti-Tumor Assessment Core, Memorial Sloan Kettering Cancer Center, New York, New York.
Elisa de StanchinaAnti-Tumor Assessment Core, Memorial Sloan Kettering Cancer Center, New York, New York.
Robert McEwenAstraZeneca Oncology, Cambridge, United Kingdom.
Marc LadanyiDepartment of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York.
Darren CrossAstraZeneca Oncology, Cambridge, United Kingdom.
William PaoDepartment of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee.
Christine M LovlyDepartment of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee. christine.lovly@vanderbilt.edu.
Vanderbilt University · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MThe Role of Focal Oncogene Amplifications in Lung CancerP01CA129243 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Andrea Ventura · 2007 to 2026
$31.2MMEDICAL SCIENTIST TRAINING PROGRAMT32GM007347 · NIGMS · VANDERBILT UNIVERSITY · PI WILLIAMS, CHRISTOPHER S. · 1985 to 2023
$26.3MVanderbilt Clinical Oncology Research Career Development ProgramK12CA090625 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Debra L. Friedman, Paula Jill Hurley · 2001 to 2026
$16.9MInterdisciplinary Training Program in Lung ResearchT32HL094296 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Ray Stokes Peebles · 2008 to 2026
$6.3MOvercoming acquired resistance to EGFR inhibitors in lung cancerR01CA121210 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI LOVLY, CHRISTINE M. · 2007 to 2016
$2.9MCancer Pharmacologist and HTS ScientistR50CA211206 · NCI · VANDERBILT UNIVERSITY · PI Joshua A. Bauer · 2016 to 2026
$1.8MNCI NIH HHS K12 CA090625NCI NIH HHS P01 CA129243NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA121210NCI NIH HHS R50 CA211206NHLBI NIH HHS T32 HL094296NIGMS NIH HHS T32 GM007347
Abstract
Mutant-selective EGFR tyrosine kinase inhibitors (TKI), such as osimertinib, are active agents for the treatment of
Indexed as
AcrylamidesAniline CompoundsAnimalsAntineoplastic AgentsDrug Resistance, NeoplasmErbB ReceptorsFemaleFocal Adhesion Protein-Tyrosine KinasesHumansIndolesLung NeoplasmsMiceMice, NudeMutationPiperazinesPyrimidinesAcrylamidesAniline CompoundsAntineoplastic AgentsErbB ReceptorsFocal Adhesion Protein-Tyrosine KinasesIndolesosimertinibPiperazinesPyrimidinessrc-Family Kinases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.